Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612591 | 0.81 | CXCR2 (0.37) | KMT2ANPC1RAB9AMAPT | |
| SCHEMBL3621875 | 0.67 | METAP1 (0.41) | KMT2AP2RX7TP53MAPT | |
| SCHEMBL3624434 | 0.67 | NPSR1 (0.40) | TP53MAPT | |
| SCHEMBL3617351 | 0.64 | MAPK14 (0.34) | — | |
| SCHEMBL3619699 | 0.64 | ALDH1A1 (0.33) | — | |
| SCHEMBL3613839 | 0.64 | MAPT (0.40) | MEN1KMT2ACYP3A4KDRMAPT | |
| SCHEMBL5764585 | 0.63 | PDK1 (0.44) | — | |
| SCHEMBL5764100 | 0.63 | PDK1 (0.44) | — | |
| SCHEMBL3621237 | 0.62 | CXCR2 (0.36) | MEN1KMT2AMAPT | |
| SCHEMBL3142232 | 0.57 | ABL1 (0.51) | MEN1KMT2AKDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267796-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2077122-A1 | THERAPEUTIC AGENTS FOR IRRITABLE BOWEL SYNDROME | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267796-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | SLC10A2, ADORA3, HRH2 | MEN1 3636/4885KMT2A 1920/4885CYP1A2 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.